Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Thermo Fisher Scientific (NYSE:TMO) & Veracyte (NASDAQ:VCYT) Financial Review
01:22am, Friday, 16'th Jan 2026
Veracyte (NASDAQ: VCYT - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesse
Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:16pm, Thursday, 15'th Jan 2026
Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
04:30pm, Sunday, 11'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and f
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 29'th Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcar
3 Medical Instrument Stocks to Counter Industry Woes Using GenAI
08:26am, Monday, 29'th Dec 2025
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
Analyzing Teleflex (NYSE:TFX) & Veracyte (NASDAQ:VCYT)
02:02am, Friday, 26'th Dec 2025
Teleflex (NYSE: TFX - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on t
Veracyte, Inc. $VCYT Shares Sold by Assenagon Asset Management S.A.
03:30am, Thursday, 25'th Dec 2025
Assenagon Asset Management S.A. decreased its position in Veracyte, Inc. (NASDAQ: VCYT) by 96.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Ex
Is This the Right Time to Add Veracyte Stock to Your Portfolio?
03:11pm, Tuesday, 23'rd Dec 2025
VCYT's Afirma and Decipher fuel strong test volume growth and a debt-free balance sheet, but rising macro costs and expenses temper the outlook.
Fisher Asset Management LLC Reduces Holdings in Veracyte, Inc. $VCYT
05:12am, Thursday, 04'th Dec 2025
Fisher Asset Management LLC lowered its position in Veracyte, Inc. (NASDAQ: VCYT) by 11.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
10:52am, Tuesday, 02'nd Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Head to Head Review: Veracyte (NASDAQ:VCYT) vs. Nanovibronix (NASDAQ:NAOV)
02:14am, Tuesday, 02'nd Dec 2025
Nanovibronix (NASDAQ: NAOV - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the
Advantage Alpha Capital Partners LP Sells 7,161 Shares of Veracyte, Inc. $VCYT
03:44am, Friday, 28'th Nov 2025
Advantage Alpha Capital Partners LP lessened its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 27.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 19
AXQ Capital LP Buys New Shares in Veracyte, Inc. $VCYT
03:36am, Tuesday, 25'th Nov 2025
AXQ Capital LP bought a new position in shares of Veracyte, Inc. (NASDAQ: VCYT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up
08:31am, Tuesday, 11'th Nov 2025
Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.
Veracyte to Participate in Upcoming Investor Conferences
08:30am, Thursday, 06'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Resea
